Key result
PCSK9 inhibitors show promise for acute and secondary prevention of ischemic stroke via atherosclerosis reduction.
This review highlights the role of PCSK9 in atherosclerosis and ischemic stroke, supporting the use of PCSK9 inhibitors for acute and secondary stroke prevention.
Proprotein convertase subtilisin/kexin type 9 (PCSK9) is a member of the proprotein convertase (PCs) family, which facilitates the degradation of low-density lipoprotein receptors (LDL-R) via intracellular and cell surface pathways, consequently elevating serum LDL-C levels. PCSK9 is implicated in various processes such as lipid metabolism, atherosclerosis, oxidative stress, inflammatory responses, thrombosis, and apoptosis. It is closely linked to ischemic stroke through its role in inducing and advancing atherosclerosis. PCSK9 inhibitors play a useful role in both acute and secondary prevention of ischemic stroke and can reduce the risk of ischemic stroke. This review examines the influence of PCSK9 on the risk factors associated with ischemic stroke and explores its potential mechanisms, and briefly describes the application of PCSK9 inhibitors in ischemic stroke.
No takes yet. Share an insight, caveat, or question.
He et al. (2025) conducted a review in Ischemic stroke. PCSK9 and PCSK9 inhibitors was evaluated. PCSK9 is linked to ischemic stroke through atherosclerosis induction, and PCSK9 inhibitors play a useful role in both acute and secondary prevention of ischemic stroke.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: